KPF
SPRY icon

K2 Principal Fund’s ARS Pharmaceuticals SPRY Stock Holding History

K2 Principal Fund’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.49M Buy
559,697
+549,497
+5,387% +$5.27M 0.31% 91
2025
Q4 		$119K Sell
10,200
-611,607
-98% -$5.95M 0.01% 315
2025
Q3 		$6.25M Buy
621,807
+304,681
+96% +$4.37M 0.51% 63
2025
Q2 		$5.53M Sell
317,126
-168,229
-35% -$2.43M 0.76% 38
2025
Q1 		$6.11M Buy
+485,355
New +$5.84M 0.77% 47
2024
Q4 		– Sell
-120,000
Closed -$1.68M – 351
2024
Q3 		$1.74M Sell
120,000
-2,341,672
-95% -$27.9M 0.25% 100
2024
Q2 		$20.9M Buy
2,461,672
+242,541
+11% +$2.15M 3.9% 1
2024
Q1 		$22.7M Sell
2,219,131
-835,202
-27% -$6.23M 3.92% 1
2023
Q4 		$16.7M Buy
3,054,333
+502,271
+20% +$2.2M 2.13% 5
2023
Q3 		$9.65M Buy
2,552,062
+1,280,318
+101% +$8.4M 2.02% 12
2023
Q2 		$8.52M Sell
1,271,744
-1,414,746
-53% -$9.44M 1.95% 17
2023
Q1 		$17.5M Sell
2,686,490
-185,658
-6% -$1.43M 2.41% 9
2022
Q4 		$24.5M Sell
2,872,148
-375,385
-12% -$2.44M 3.72% 6
2022
Q3 		$16.9M Buy
3,247,533
+1,705,827
+111% +$8.41M 1.94% 12
2022
Q2 		$6.54M Buy
+1,541,706
New +$5.38M 0.72% 43

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

K2 Principal Fund's SPRY Position: Q1 2026 in Review

K2 Principal Fund increased its ARS Pharmaceuticals (SPRY) stake by 5,387% in Q1 2026, buying an estimated $5.27M and bringing the position to 559,697 shares worth $4.49M. The position accounts for 0.31% of the portfolio, ranked #91.

K2 Principal Fund first reported a position in SPRY in Q2 2022 and has held it in 15 quarters since. The position peaked at $24.5M in Q4 2022. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • K2 Principal Fund held 559,697 shares of ARS Pharmaceuticals worth $4.49M as of Q1 2026.
  • K2 Principal Fund bought 549,497 ARS Pharmaceuticals shares in Q1 2026, an estimated $5.27M.
  • ARS Pharmaceuticals made up 0.31% of K2 Principal Fund's portfolio in Q1 2026, its #91 holding.
  • K2 Principal Fund first reported a position in ARS Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
  • K2 Principal Fund's ARS Pharmaceuticals position peaked at $24.5M in Q4 2022.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on K2 Principal Fund's 13F filing for Q1 2026, filed 14 May 2026.